Literature DB >> 21219678

The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes.

M C Walsh1, A J Camerlin, R Miles, P Pino, P Martinez, F Mora-Guzmán, J G Crespo-Solis, S P Fisher-Hoch, J B McCormick, B I Restrepo.   

Abstract

SETTING AND
OBJECTIVES: the sensitivity of the interferon-gamma release assays (IGRAs) in the detection of Mycobacterium tuberculosis infection or disease may be affected by immune dysregulation in diabetes. As millions of type 2 diabetes patients are at risk for tuberculosis (TB) worldwide, it is important to determine if the sensitivity of IGRAs is compromised in this vulnerable population.
DESIGN: the sensitivity of the IGRAs QuantiFERON®-TB Gold (QFT-G) and T-SPOT®.TB was evaluated among specimens from newly diagnosed adults with microbiologically confirmed TB with and without diabetes. We also evaluated the association between QFT-G results and diabetes-associated conditions (dyslipidemia, obesity).
RESULTS: QFT-G sensitivity was 70% among TB patients. Patients with diabetes, chronic hyperglycemia or overweight/obesity were more than twice as likely to have positive test results in multivariate models (P < 0.05). Low high-density lipoprotein cholesterol or high triglycerides were not associated with assay results. In a separate group of TB patients (n = 43), T-SPOT.TB was 93% sensitive, with similar performance in patients with and without diabetes.
CONCLUSION: IGRA sensitivity is not compromised by diabetes in TB patients. Accordingly, IGRAs may also be suitable for diagnosing TB infection in diabetes patients, which is required to assess TB risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219678      PMCID: PMC3085021     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   3.427


  30 in total

1.  Using tests for latent tuberculous infection to diagnose active tuberculosis: can we eat our cake and have it too?

Authors:  Dick Menzies
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

Review 2.  Defects in the interferon-gamma and interleukin-12 pathways.

Authors:  Sergio D Rosenzweig; Steven M Holland
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

3.  Defining the research agenda to reduce the joint burden of disease from diabetes mellitus and tuberculosis.

Authors:  Anthony D Harries; Megan B Murray; Christie Y Jeon; Salah-Eddine Ottmani; Knut Lonnroth; Mauricio L Barreto; Nils Billo; Richard Brostrom; Ib Christian Bygbjerg; Susan Fisher-Hoch; Toru Mori; Kaushik Ramaiya; Gojka Roglic; Hanne Strandgaard; Nigel Unwin; Vijay Viswanathan; David Whiting; Anil Kapur
Journal:  Trop Med Int Health       Date:  2010-04-12       Impact factor: 2.622

Review 4.  T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings.

Authors:  Keertan Dheda; Richard van Zyl Smit; Motasim Badri; Madhukar Pai
Journal:  Curr Opin Pulm Med       Date:  2009-05       Impact factor: 3.155

5.  Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis.

Authors:  So Young Park; Kyeongman Jeon; Sang-Won Um; O Jung Kwon; Eun-Suk Kang; Won-Jung Koh
Journal:  Scand J Infect Dis       Date:  2009

6.  Hypercholesterolemia impairs immunity to tuberculosis.

Authors:  Gregory W Martens; Meltem Cevik Arikan; Jinhee Lee; Fucheng Ren; Therese Vallerskog; Hardy Kornfeld
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

7.  Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients.

Authors:  Y Kobashi; K Mouri; Y Obase; M Fukuda; N Miyashita; M Oka
Journal:  Eur Respir J       Date:  2007-07-25       Impact factor: 16.671

Review 8.  Diabetes and the risk of tuberculosis: a neglected threat to public health?

Authors:  Catherine R Stevenson; Julia A Critchley; Nita G Forouhi; Gojka Roglic; Brian G Williams; Christopher Dye; Nigel C Unwin
Journal:  Chronic Illn       Date:  2007-09

9.  Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.

Authors:  Blanca I Restrepo; Susan P Fisher-Hoch; Paula A Pino; Adrian Salinas; Mohammad H Rahbar; Francisco Mora; Nicolas Cortes-Penfield; Joseph B McCormick
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 20.999

Review 10.  Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies.

Authors:  Christie Y Jeon; Megan B Murray
Journal:  PLoS Med       Date:  2008-07-15       Impact factor: 11.069

View more
  19 in total

Review 1.  Diabetes and Tuberculosis.

Authors:  Blanca I Restrepo
Journal:  Microbiol Spectr       Date:  2016-12

2.  Prevalence of dysglycemia and clinical presentation of pulmonary tuberculosis in Western India.

Authors:  V Mave; S Meshram; R Lokhande; D Kadam; S Dharmshale; R Bharadwaj; A Kagal; N Pradhan; S Deshmukh; S Atre; T Sahasrabudhe; M Barthwal; S Meshram; A Kakrani; V Kulkarni; S Raskar; N Suryavanshi; R Shivakoti; S Chon; E Selvin; A Gupte; A Gupta; N Gupte; J E Golub
Journal:  Int J Tuberc Lung Dis       Date:  2017-12-01       Impact factor: 2.373

3.  Adults with Mycobacterium tuberculosis infection and pre-diabetes have increased levels of QuantiFERON interferon-gamma responses.

Authors:  Matthew J Magee; Susanna L Trost; Argita D Salindri; Genet Amere; Cheryl L Day; Neel R Gandhi
Journal:  Tuberculosis (Edinb)       Date:  2020-04-02       Impact factor: 3.131

Review 4.  Influence of diabetes mellitus on immunity to human tuberculosis.

Authors:  Pavan Kumar Nathella; Subash Babu
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

Review 5.  Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms.

Authors:  Katharina Ronacher; Reinout van Crevel; Julia A Critchley; Andrew A Bremer; Larry S Schlesinger; Anil Kapur; Randall Basaraba; Hardy Kornfeld; Blanca I Restrepo
Journal:  Chest       Date:  2017-04-20       Impact factor: 9.410

Review 6.  Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management.

Authors:  Julia A Critchley; Blanca I Restrepo; Katharina Ronacher; Anil Kapur; Andrew A Bremer; Larry S Schlesinger; Randall Basaraba; Hardy Kornfeld; Reinout van Crevel
Journal:  Chest       Date:  2017-04-20       Impact factor: 9.410

Review 7.  Impact of diabetes on the natural history of tuberculosis.

Authors:  Blanca I Restrepo; Larry S Schlesinger
Journal:  Diabetes Res Clin Pract       Date:  2014-07-14       Impact factor: 5.602

8.  Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity.

Authors:  Samuel S Stew; Perla J Martinez; Larry S Schlesinger; Blanca I Restrepo
Journal:  Tuberculosis (Edinb)       Date:  2013-12       Impact factor: 2.973

Review 9.  Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus.

Authors:  Blanca I Restrepo; Larry S Schlesinger
Journal:  Tuberculosis (Edinb)       Date:  2013-12       Impact factor: 2.973

10.  Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.

Authors:  Leonardo Martinez; Limei Zhu; Maria E Castellanos; Qiao Liu; Cheng Chen; Benjamin D Hallowell; Christopher C Whalen
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.